Eli Lilly (NYSE:LLY) Sees 1.59% Rise As Jaypirca Secures Positive EU Opinion
Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in ...
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Is Eli Lilly Stock a Buy?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup
An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...
BioPharma Dive4d
Novo’s Wegovy successor disappoints in second large trial
A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...
Nasdaq3d
Why Eli Lilly Stock Flopped Today
Eli Lilly (NYSE: LLY) stock has had plenty of good ... Learn More » That morning, Wegovy maker Novo Nordisk announced the latest clinical trial results for an advanced obesity drug it's ...
Eli Lilly's first weight loss pill could expand access to GLP-1s around the globe, executive says
Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.